Phase 1 DISP-10 Trial for Advanced GI Cancers
Summary
NIH registered a Phase 1 multicenter open-label study (NCT07544589) evaluating DISP-10, a combination therapy of DV-10 adenovirus and idecabtagene vicleucel (BCMA-directed CAR-T), in adult participants with advanced gastrointestinal cancers including colorectal, gastric, esophageal, and gastroesophageal adenocarcinoma. The trial consists of dose-escalation (Part 1) to establish a recommended dose for expansion, followed by dose-expansion (Part 2) to evaluate safety and efficacy at that dose.
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.
What changed
NIH registered a new Phase 1 clinical trial (NCT07544589) for DISP-10, a combination of DV-10 adenovirus and idecabtagene vicleucel CAR-T therapy, in patients with advanced colorectal, gastric, esophageal, and gastroesophageal adenocarcinoma. The two-part design includes dose-escalation to determine a recommended dose for expansion and subsequent dose-expansion for safety and efficacy evaluation.
Affected parties include oncology research centers conducting GI cancer trials, pharmaceutical companies developing CAR-T combination therapies, and patients with advanced GI cancers seeking experimental options. The trial's BCMA-targeting mechanism in GI malignancies represents a novel application warranting monitoring for similar research programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Phase 1 NCT07544589 Kind: PHASE1 Apr 22, 2026
Abstract
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor [CAR] T), in adult participants with advanced gastrointestinal (GI) cancers.
The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.
Conditions: Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma
Interventions: DISP-10
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.